COverview
Children's Hospital Los Angeles provides specialized medical care for children. It delivers a wide range of pediatric services through its hospital and affiliated programs, treating patients across many departments and subspecialties. The hospital operates by providing clinical care, family-centered support, and research-driven practices to improve outcomes for children. Its distinguishing features include Magnet designation, a focus on compassionate, high-quality care, and a large annual patient volume (over 528,000 visits). The goal is to relieve pain and suffering for children, advance pediatric medicine, and ensure access to the highest standard of care for kids.
Work here?Claim your company
About Children's Hospital Los Angeles
Industries
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$36.9M
Headquarters
Bellflower, CA
Founded
1901
Get referred to Children's Hospital Los Angeles
See people who can refer or advise you
Simplify's take
What believers are saying
- The $1.35 billion Anniversary Campaign closed October 2026, funding expansion, recruitment, and research.
- DSRD symposium and first clinical trial position CHLA as a national Down syndrome neurology leader.
- New 2026 trials in CAR-T, sickle cell gene editing, and cardiac lymphatics deepen pipeline.
What critics are saying
- Cardiology fell to No. 20 nationally, exposing pressure from UCLA, Cedars-Sinai, and Rady competition.
- Gene therapy programs face toxicity scrutiny; CHLA must prevent liver, heart, and muscle complications.
- A major pediatric safety scandal would crush donor confidence, referrals, and the brand.
What makes Children's Hospital Los Angeles unique
- CHLA's 18-year Honor Roll streak and 2026-27 No. 1 California ranking signal durable clinical breadth.
- Saban Research Institute supports nearly 600 active trials, converting research into referral gravity.
- Heart Institute, Urology, and Neurology rank top ten nationally, attracting complex cases.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$36.9M
Above
Industry Average
Funded Over
4 Rounds
Company News
Putting patients and families at the Center of Bladder Exstrophy care. November 2, 2026 by Katie Sweeney The 2026 Association for the Bladder Exstrophy Community conference at CHLA combined clinical education with family-led conversations. This summer, Children's Hospital Los Angeles hosted the annual Association for the Bladder Exstrophy Community (ABEC) conference, bringing together nearly 100 patients and families from across the country and globe. As one of just 10 ABEC Centers of Excellence nationwide, CHLA is a major referral center for bladder exstrophy, a rare and complex condition in which the bladder and related organs develop outside a baby's body. Along with educational sessions on the latest surgical and medical approaches, this year's conference offered expanded opportunities for patients and families to learn from each other. "We put the families front and center," says Joan Ko, MD, Associate Chief of Urology, Director of the Complex Pediatric Reconstructive Urology Program, and Co-Director of the Colorectal and Pelvic Anomalies Center at CHLA. "We wanted it to focus on what is most important to them as they navigate the challenges of living with this condition." Sharing expertise across specialties. At the conference, held July 17-18, CHLA specialists shared expertise on issues that can affect people with bladder exstrophy throughout childhood and beyond. Presenters included: * Scott Sparks, MD, Surgical Director of the Comprehensive Urinary Stone Program at CHLA, who discussed kidney and bladder stones * Jaya Punati, MD, a pediatric gastroenterologist and Co-Director of the Colorectal and Pelvic Anomalies Center, who discussed constipation in patients with bladder exstrophy * Michelle SooHoo, PhD, a clinical psychologist dedicated to Urology, who shared strategies to help children, teens, and adults stay engaged with their medical care In addition, a large portion of the conference was dedicated to small-group discussions led by two adults with bladder exstrophy and the mother of a child with the condition. Physicians and other specialists participated as clinical resources, but patients and families drove the conversations. Whom do you tell about bladder exstrophy? One of the most compelling discussions focused on a challenging question many families grapple with: Whom do you tell that your child has bladder exstrophy? Parents first shared how they try to balance their child's privacy with the need for support from family and others. When organizers posed the same question to teens and adults with bladder exstrophy, perspectives varied widely. Some were glad that people around them knew about their condition; others wanted to decide for themselves when to share that information. "There isn't one right answer," Dr. Ko says. "It is a very personal decision to make as a family." Learning from patients of all ages. For Dr. Ko, the conference reinforced the importance of connecting patients with specialists who have extensive expertise in treating this rare condition. "Some institutions never see a child with bladder exstrophy," she notes. "It's critical that patients and families are seen at a Center of Excellence like CHLA." Adult attendees also shared their experiences living with this condition over the long term. "Seeing so many adults with bladder exstrophy who are healthy and thriving was inspiring," Dr. Ko says. "It's a reminder of the impact we can have by providing the right care early on."
CHLA-Led symposium highlights emerging treatments for Down Syndrome Regression Disorder. October 29, 2026 by Parker Danowski A world leader in DSRD, CHLA convened experts and families from across the country to share the latest research and approaches to care. Hundreds of clinicians, researchers, self-advocates, and families gathered at Children's Hospital Los Angeles recently for the second annual Down Syndrome Regression Disorder (DSRD) Symposium. The event was led by Jonathan D. Santoro, MD, Chief of Neurology, Co-Director of the Neurological Institute, and the Las Madrinas Chair in Neurology at CHLA. Dr. Santoro is one of the world's foremost experts on DSRD, a rare condition that can cause people with Down syndrome to suddenly lose the ability to communicate, eat, move, and perform everyday activities. Held Sept. 26 at The Saban Research Institute of Children's Hospital Los Angeles and virtually, the symposium highlighted new research and advances in care while giving patients and families an opportunity to connect and share their experiences. The symposium was organized by Lina Nguyen, RN, a nurse who works in Dr. Santoro's Strategic Therapies for Overcoming Reactive iMmunology (STORM) Lab. CHLA experts accelerate DSRD research. Since 2019, Dr. Santoro and his colleagues have led breakthrough research to deepen the understanding of DSRD and improve treatments. To highlight the progress made, Dr. Santoro showed a photo of a rocket launching into space during his opening address. "This is where we're headed," he told attendees. "We have accomplished so much already, and there is so much more to come." That progress includes the first DSRD-focused clinical trial - a collaboration between Children's Hospital Los Angeles and the University of Colorado and Children's Hospital Colorado that is investigating the safety and effectiveness of three different treatments for DSRD, including immunotherapies such as intravenous immunoglobulin (IVIg). The symposium also featured experts from institutions across the country, including Kate Westmoreland, MD, of the University of North Carolina at Chapel Hill; Aaron Besterman, MD, of the University of California San Diego; Ryan Kammeyer, MD, of the University of Colorado and Children's Hospital Colorado; and Kara Thompson, DO, of MercyOne. Speakers addressed key questions in DSRD diagnosis and care, including how to distinguish the condition from other disorders, recognize and treat catatonia, and manage its medical, psychiatric, and immune symptoms. Presentations also explored the potential role of blood-brain barrier dysfunction and whether GLP-1 receptor agonists could have future applications in DSRD treatment. A personalized medicine approach to DSRD treatment. In the symposium's keynote address, Dr. Santoro detailed the use of neurodiagnostic testing and how this leads to treatment selection by clinicians. He then explained how profiles of cerebrospinal fluid samples may help predict how well an individual will respond to certain immunotherapies, particularly Janus Kinase (JAK) inhibitors and B-cell depletion therapies. These data have now opened the door for personalized medicine approaches to treating DSRD for the first time. Additionally, he detailed how a novel autoantibody against parvalbumin interneurons could potentially be causing DSRD, though additional research is needed. Dr. Santoro also provided an update on the first clinical trial focused on DSRD, which CHLA co-led with Children's Hospital Colorado and the University of Colorado. Results are expected to be published next year. He later described the team's next clinical trial, which will test the immunotherapy ublituximab (Briumvi) in treating DSRD. He also touched on efforts to more specifically identify the causes of DSRD and how knowledge gained from DSRD treatments may help inform care for other neurologic diseases in people with Down syndrome, such as autism spectrum disorder, moyamoya vasculopathy, epilepsy, and potentially even Alzheimer's disease. He emphasized the importance of families sharing their personal DSRD stories. "You are the key to spreading the word on DSRD and helping an individual get diagnosed and treated quickly," Dr. Santoro told families. Patients highlight the impact of DSRD research. One of the highlights of the event was the opportunity for individuals with Down syndrome and DSRD to share their own stories. Ryan, who has Down syndrome but does not have DSRD, spoke about why he chose to participate in DSRD research as a healthy control. Meanwhile, Darci, a Special Olympics athlete who was treated for DSRD by Dr. Santoro, shared how she is now returning to the sports and the life she loves. "I've been traveling a lot, enjoying the outdoors, and kayaking," Darci said. "I get to compete in sports, I won some medals, and I also got back into public speaking. I couldn't do it without Dr. Santoro. I want to say thank you, and never give up."
St. Luke's welcomes pediatric neurologist who will be vice chair of Pediatrics. By St. Luke's University Health Network Published October 28, 2026 at 4:09 PM Last updated October 28, 2026 at 4:09 PM Leigh Ramos-Platt, MD, a pediatric neurologist with special qualifications in child neurology and clinical neurophysiology, recently joined St. Luke's Children's Hospital. She will also serve as vice chair of Pediatrics. Dr. Ramos-Platt came East from The Children's Hospital of Los Angeles, bringing her expertise in genetic therapy and other treatments for Duchenne and Spinal Muscular Atrophy, both genetic diseases that cause progressive muscle weakness. "I'm excited to come to this progressive, growing and friendly system with a goal of working with expert teams to help improve quality of life in pediatric patients who suffer from these and other neurologic conditions, which can be either genetic or acquired," said Dr. Ramos-Platt, who lives in Bethlehem. Get local news you can trust in your inbox. A graduate of the John A. Burns School of Medicine at the University of Hawai'i, Dr. Ramos-Platt completed residencies in general pediatrics and neurology at Loma Linda University Hospital Medical Center, California, and the Medical College of Wisconsin Affiliated Hospitals (Children's Hospital of Wisconsin), respectively. Her fellowship was in clinical neurophysiology at the Medical College of Wisconsin Affiliated Hospitals, where she was the first pediatric fellow. She earned an MBA from Eastern University. She explains that her lifelong medical passion is "anything electric affecting kids' muscles and nerves." Bringing advanced therapies to St. Luke's, she says, "will ease the burden on patients and families so they don't have to travel to New York or Philadelphia for this specialty medical care." The recent additions of Dr. Ramos-Platt and Amisha Jain, MD, pediatric Pulmonologist and co-division chief of Pediatric Specialty Care expand St. Luke's expert care across more than 40 pediatric subspecialties, noted Jessika Haynos, Vice President, Women's and Children's Service Lines at St. Luke's University Health Network. "St. Luke's Children's Hospital is committed to providing families with the best primary and specialty care for their children," Haynos said. "By adding Dr. Ramos-Platt's expertise in pediatric neurology, we have expanded the care options available to families across the region." Dr. Ramos-Platt plans to begin introducing neuromuscular gene transfer programs at St. Luke's, which have been bringing "great outcomes" in advanced, specialty centers both nationally and worldwide. "There are hundreds of gene therapy trials active or planned for neurological conditions," Dr. Ramos-Platt adds. "I'm excited to help bring this treatment to St. Luke's." In 2020, at The Children's Hospital Los Angeles, she treated a baby with spinal muscular atrophy who was the first such baby to be referred to the hospital through California's then newly expanded newborn screening program. (See article:Gene Therapy Saves Greigh From a Paralyzing Muscle Disease | Children's Hospital Los Angeles.) Dr. Ramos-Platt and her husband, Lorne Platt, who has a PhD in geography and teaches geography and urban planning at West Chester University, recently became empty nesters. Their son is a graduate student at Wake Forest University, and their daughter a freshman at Grinnell College in Iowa, where she's on their tennis team. Dr. Ramos-Platt plans to take a medical-mission trip to Cambodia this fall as a volunteer and president of "Neuroscience for All," a not-for-profit whose mission is to contribute neurologic clinical education and equipment to support patient care in the country whose doctors were killed during the 1970s, she said. She speaks English, some Spanish, a little Mandarin and some Khmer, the national language of Cambodia. She is also on the board of Hunter's Heart Foundation, a non-profit formed to increase awareness and connection for families who have been given the diagnosis of Duchenne Muscular Dystrophy. When Dr. Ramos-Platt wants to relax, she bakes, jogs, makes jewelry, and takes care the family's animals, all rescues: a Schnoodle (Buttons), two bunnies (River and Lilly) and two Guinea pigs (Selyse and Gimbap). Editor's Note: This advertorial content is being published by TAPinto.net as a service for its marketing partners. For more information about how to market your business or nonprofit on TAPinto, please visit TAPintoMarketing.net or email [email protected]. The opinions expressed herein, if any, are the writer's alone, and do not reflect the opinions of TAPinto.net or anyone who works for TAPinto.net. TAPinto.net is not responsible for the accuracy of any of the information supplied by the writer. Get More TAPinto Local News on Google
"Children's Hospital Los Angeles" discusses safety of gene therapies Rohit Kohli speaking during the "Health" International Pediatrics Conference (WAM) 18 October 2026 01:39 Abu Dhabi (WAM) Children's Hospital Los Angeles in the United States reviewed, during its participation in a session titled "Gene Therapy and Rare Disorders in Children," within the 20th edition of the "Health" International Pediatrics Conference in Abu Dhabi, the mechanisms of toxicity associated with gene therapies and their potential effects on the liver, heart, and muscles, and ways to reduce their risks through modifying viral vectors, preemptive immunosuppression, and standardizing patient follow-up protocols. Dr. Rohit Kohli, head of the Division of Gastroenterology, Hepatology and Nutrition at the hospital, said that toxicity associated with gene therapies is multifactorial and may be linked to the characteristics of the viral vector, the nature of the disease, or the patient's immune response, noting the importance of identifying risk factors and establishing unified mechanisms for monitoring and managing complications, ensuring long-term patient follow-up. Databases Rohit Kohli stressed the importance of standardizing treatment protocols and patient follow-up mechanisms, based on expertise gained from organ transplantation during the 1980s and 1990s, allowing for evaluation of treatment changes and their impact on outcomes, and adoption of unified pathways for managing elevated liver enzymes, myositis, and thrombotic microangiopathy. He emphasized the importance of building more comprehensive databases that allow follow-up of children with various genetic disorders and analysis of treatment outcomes across medical specialties.
Children's Hospital Los Angeles 2026 gala will honor Ellen K and Kourtney & Justin Turner. September 30, 2026 GRAMMY winner Michael Bublé headlines and Gina Rodriguez hosts the biennial CHLA Gala on Saturday, Oct. 17 in Los Angeles. LOS ANGELES, CA (September 30, 2026) - Children's Hospital Los Angeles (CHLA) has announced the Courage to Care Award recipients, along with an acclaimed lineup of talent and special guests for the 2026 CHLA Gala, taking place Saturday, October 17, at The Event Deck at L.A. LIVE in downtown Los Angeles. The signature biennial event will celebrate CHLA's 125-year legacy of advancing pediatric medicine while honoring the extraordinary philanthropists, advocates, families, and CHLA team members who make the hospital's mission possible. The evening will also highlight CHLA's historic $1.25 billion Anniversary Campaign, which supports the future of pediatric healthcare, research, and education. Headlining the evening will be Michael Bublé, the GRAMMY Award-winning global superstar whose career includes more than 75 million albums sold worldwide. Bublé has earned five GRAMMY Awards, 15 JUNO Awards, a star on the Hollywood Walk of Fame, and a place on Canada's Walk of Fame. Golden Globe Award-winning actress Gina Rodriguez, beloved for her breakout role in "Jane the Virgin," will serve as host for the evening's celebration. Rodriguez, a series regular on ABC's "Will Trent," is currently making her feature directorial debut with an upcoming boxing drama, which she also co-wrote, directs, and stars in. Two-time Olympian and gold medalist Jordan Chiles will present the Gala's 2026 Mission Moment, spotlighting the Jackie and Gene Autry Orthopedic Center at CHLA and the life-changing care it provides to thousands of children each year. Through innovative treatment, rehabilitation, and research, the center helps young patients overcome complex orthopedic conditions and achieve their fullest potential. CHLA's Anniversary Campaign Co-Chairs Nikki DeLoach and Jeffrey Worthe will be on hand to celebrate the hospital's 125th anniversary. CHLA also thanks Honorary Campaign Chairs and longtime CHLA advocates Jamie Lee Curtis, Jimmy Kimmel, Sugar Ray Leonard, and Chuck Lorre, for supporting the campaign. "As Children's Hospital Los Angeles marks 125 years of caring for children and families, this Gala is a meaningful celebration of the community that makes our mission possible," said Paul S. Viviano, President and Chief Executive Officer at CHLA. "We are deeply grateful to Anniversary Campaign Co-Chairs Jeffrey Worthe and Nikki DeLoach for their leadership, to Ellen K and Kourtney and Justin Turner for their steadfast commitment to children, and to Michael Bublé and Gina Rodriguez for bringing their extraordinary talents to this milestone evening." The gala will feature a red carpet, cocktail reception, dinner, and an after-party featuring DJ Dense, who is the official DJ and host for the Los Angeles Clippers. The evening benefits Children's Hospital Los Angeles to help ensure the hospital continues to deliver world-class, compassionate care while advancing pioneering research and field-leading education that improve the lives of children throughout Southern California and around the world. Sponsors of the 2026 CHLA Gala include: Costco Wholesale, The Paul Ferrante Foundation, The Alesia Alpert Family Foundation, Danhakl Family Foundation, The Friese Foundation, AltaMed Health Services, The Chuck Lorre Family Foundation, Marta Eliza Miller Foundation, Eastdil Secured - Roy March, Jay Borzi, Michael Van Konynenburg, Steve Silk and Adam Edwards, Morgan Adams, Inc. and SLH Investments, The Roski Family, Lana and Tony Safoian, and The Tesoriero Family. About Children's Hospital Los Angeles. Children's Hospital Los Angeles is at the forefront of pediatric medicine and is the largest provider of hospital care for children in California. In the 125 years since its founding in 1901, CHLA has delivered a level of pediatric care that is among the best in the world. Ranked among the top 10 children's hospitals in the nation by U.S. News & World Report, Children's Hospital Los Angeles provides comprehensive and compassionate care to one of the largest and most diverse pediatric patient populations in the country. The hospital is ranked No. 1 in California and among the top-ranked children's hospitals in the Pacific U.S. region for 2026-27. CHLA is also ranked No. 5 globally in Newsweek's World's Best Specialized Hospitals 2027 - Pediatrics. A leader in pediatric research, CHLA is among the top ten children's hospitals for research funding from the National Institutes of Health. The Saban Research Institute of Children's Hospital Los Angeles supports the full continuum of research, translating scientific discoveries into life-changing treatments for patients around the globe. As a pediatric academic medical center, CHLA is also home to the Chuck Lorre Pediatric Health Education Institute, which encompasses education programs throughout the institution. The hospital's commitment to building stronger, healthier communities is evident in CHLA's efforts to enhance health education and literacy, introduce more people to careers in healthcare, and fight food insecurity. To learn more, follow CHLA on Facebook, Instagram, LinkedIn, YouTube, and X, and visit CHLA.org.
There are no jobs for Children's Hospital Los Angeles right now.
Find jobs on Simplify and start your career today
We update Children's Hospital Los Angeles's jobs every few hours, so check again soon!Browse all jobs
About Children's Hospital Los Angeles
Industries
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$36.9M
Headquarters
Bellflower, CA
Founded
1901
There are no jobs for Children's Hospital Los Angeles right now.
Find jobs on Simplify and start your career today
We update Children's Hospital Los Angeles's jobs every few hours, so check again soon!Browse all jobs